Galectin Therapeutics
GALT
GALT
60 hedge funds and large institutions have $36.2M invested in Galectin Therapeutics in 2018 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 20 increasing their positions, 12 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
27% less call options, than puts
Call options by funds: $2.91M | Put options by funds: $3.98M
43% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 21
Holders
60
Holding in Top 10
–
Calls
$2.91M
Puts
$3.98M
Top Buyers
| 1 | +$1.56M | |
| 2 | +$1.48M | |
| 3 | +$1.36M | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$568K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$547K |
Top Sellers
| 1 | -$1.39M | |
| 2 | -$1.05M | |
| 3 | -$369K | |
| 4 |
IG
ING Group
Amsterdam,
Netherlands
|
-$318K |
| 5 |
Renaissance Technologies
New York
|
-$237K |